Subscribe To
Processa pharmaceuticals to present at the thinkequity conference
HANOVER, MD, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage p...
October 13, 2023, 1:08 pm
Eu regulator backs pfizer's blood cancer therapy
The European Union medicines regulator on Friday recommended a conditional marketing authorization for U.S. drugmaker Pfizer's therapy for a type of b...
October 13, 2023, 8:05 am
Lantheus: fast-growing radiotherapeutics specialist can benefit from lilly's point biopharma takeover
Lantheus Holdings' stock price has increased more than 1000% since its IPO in 2015, with most gains occurring since 2022. The success of its product P...
October 12, 2023, 4:35 pm
Phio jumps 91% on encouraging preclinical cancer drug data
Data from preclinical studies show that Phio's (PHIO) cancer drug PH-894 is effective in BRD4 inhibitio...
October 12, 2023, 12:47 pm
Tempest (tpst) up as first-line liver cancer study meets goals
Tempest (TPST) skyrockets 2879% on positive new and updated findings from its early-mid-stage study evaluating TPST-1120 in combination with standard-...
October 12, 2023, 12:01 pm
Olema oncology kat6 inhibitor compounds demonstrate potent anti-tumor activity
Preclinical data to be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and ...
October 12, 2023, 11:01 am
Illumina ordered by european commission to sell cancer test maker grail
Illumina Inc (NASDAQ:ILMN), a genetic testing company, has been ordered by EU antitrust regulators to sell Grail after closing its takeover of the
October 12, 2023, 9:17 am
Pfizer's lung cancer combination therapy approved by the fda
Pfizer Inc (NYSE:PFE) announced that the United States Food and Drug Administration (FDA) has approved BRAFTOVI (encorafenib) plus MEKTOVI (binimetin...
October 12, 2023, 8:41 am
Jaguar health to present october 17 at the lytham partners fall 2023 investor conference and october 18 at the bio investor forum
Top line results expected in the coming weeks for company's phase 3 OnTarget trial of crofelemer for preventative treatment of ...
October 12, 2023, 8:30 am
Fda approves pfizer's braftovi plus mektovi for a type of non-small cell lung cancer
Pfizer Inc. PFE, -0.18% said Thursday the U.S. Food and Drug Administration has approved its Braftovi plus Mektovi combination therapy as a treatment ...
October 12, 2023, 6:56 am
Illumina ordered by eu antitrust regulators to sell grail
U.S. genetic testing company Illumina has been ordered by EU antitrust regulators to sell cancer test m...
October 12, 2023, 5:56 am
Y-mabs: they have earnings, but still seek the big hit
Y-mAbs Therapeutics is undervalued despite growing sales of their approved cancer therapy, presenting a...
October 11, 2023, 7:14 pm
Wall street warms up to tempest as tpst stock surges 1,500%
Tempest Therapeutics (NASDAQ: TPST ) is the stock to watch for today, as its shares are up by a staggering 1,500%. This morning, the ...
October 11, 2023, 12:54 pm
Tempest therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise
Shares of Tempest Therapeutics Inc. TPST, +1942.52% soared more than 1,900% on Wednesday after the company released study results for its investigatio...
October 11, 2023, 12:29 pm
Pmv pharmaceuticals to present updated phase 1 data on pc14586 at the 2023 aacr-nci-eortc international conference on molecular targets and cancer therapeutics and host a kol webinar
PRINCETON, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery an...
October 11, 2023, 12:00 pm
Phio pharmaceuticals presents new data for targeting of brd4 with its intasyl™ compound ph-894
–Preclinical data shows melanoma cells treated with PH-894 makes them more recognizable to immune cells, increasing potential for elimination –Pre...
October 11, 2023, 11:30 am
1 beaten-down healthcare stock to buy and hold for 10 years
Guardant Health's various products are all designed to help physicians and patients fight cancer. The c...
October 11, 2023, 9:53 am
Gsk settles zantac cases after claims popular heartburn drug causes cancer
The pharma giant settled four cases in California for an undisclosed amount to avoid the “distraction” of a trial....
October 11, 2023, 8:30 am
Gsk strikes legal settlement over heartburn drug zantac
GSK PLC (LSE:GSK, NYSE:GSK) has struck a deal to stop a high profile case concerning its heartburn drug Zantac heading to court in California. The FTS...
October 11, 2023, 2:24 am
Gsk reaches confidential settlement in california zantac lawsuit
GSK on Wednesday said it had reached a confidential settlement on a litigation in California over claims that the British drugmaker's heartburn drug Z...
October 11, 2023, 2:13 am